The Collective of Experts at Devinebio

Devinebio has assembled a collection of drug development experts. The help us implement the Devine Process that cover activities ranging from early discovery into early clinical development.

We have both internal and external focus for this expert team:

  • Internal: fostering growth Special Purpose Exit Companies (SPECs). In partnership with Patent Advocacy Group and their advisors, we form a SPEC and use the Collective of Experts team uses the Devine Process to mature drug assets in a given rare disease towards market approval.

  • External: The Collective of Experts team use the Devine Process to provide efficient drug development solutions for Life Science companies. We aid in commercializing therapeutics for Small Molecules, Biologics and Advanced Therapeutics. The Devine Process accesses expert talent, at the right time, and at the right place of need, to help keep the drug development pipeline on track.

Bottomline, the Collective of Experts provides just-in-time solutions, at the right time and place where they are most needed. Devine Process - providing the accelerated path towards market approval.

Chris Hopkins, PhD, MBA

Target ID, Drug Discovery, Corporate Relations

Russ Teichert, PhD, MBA

iPSC Assay Development, Drug Screens, High Content imaging

Thomas Caulfield, PhD

Molecular Dynamics Modeling, AI Smart Library Generation

Michelle Mc Guinness, MSc

Regulatory Strategy, Drug Development, Health Authority Liaison

Simon Sydserff, PhD

Drug Discovery, Neurology and cardiology, Disease Model Creation

Y. Shrike Zhang, PhD, MD

Microphysological Systems, Bimedical Engineering, Microfluidics

Immunological Drug Development, Vaccine Therapies in Oncology, iPSC Platforms for Drug Discovery

Priority Review Vouchers, Alternative Funding, Drug Hunting, Startups.

Toxicology Studies, ADME Parameters, Rare Diseases

John Lincecum, PhD

Neurodegeneration models, drug discovery and development

Brett Crockett, JD

Patents, IP licensing, Dispute Resolution

Todd Verdoorn, PhD

Neuropharmacology, biomarker development, Statistics

Anne Taylor, PhD

Microfludics, Neuromuscular Junction Models, iPSC-based Systems

Ricky Solorzano

Bioprinting, Vascular 3D models, Venture Architect

Suzanne Hendrix, PhD

Data Managment Services, Statistical Analysis Plans, Strategic Planning

The Collective of Experts team expertise covers Drug-Protein Interaction Modeling, Smart Library Generation, High-throughput and High-content Assay Development, Animal Model Development, FDA Regulatory Filings, Chemistry-Manufacturing-Controls, and Clinical Trials Planning, and more.